Four new value-creating milestones achieved in the epilepsy project CG01!

CombiGene’s epilepsy project CG01 continues to show strength. During spring and summer, as many as four value-creating milestones were achieved: the release of plasmids for GMP production, completed GMP production, initiated optimization of the administration of CG01 in large animal studies, and the approval of patents in the U.S. and Russia.

CombiGene’s epilepsy project is now approaching the final stage of the preclinical phase. The results of the now initiated study of optimized administration of CG01 are expected to be completed in late summer 2021. A positive outcome will mean that the long-term preclinical studies in toxicology and biodistribution in large animals can start after the summer as planned. During the autumn of 2021 and in parallel with the studies in toxicology and biodistribution, we will conduct quality analyses of the GMP produced CG01 material, which will used in the first human study. These analyses will continue for the most part of autumn 2021.

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Agavägen 52A, SE-181 55 Lidingö

 

Linked In     Twitter      Facebook